Molecular Formula | C19H26N2S |
Molar Mass | 314.49 |
Density | 1.124±0.06 g/cm3(Predicted) |
Melting Point | 207.5 °C |
Boling Point | 491.3±35.0 °C(Predicted) |
pKa | 17.66±0.40(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Physical and Chemical Properties | Chemical properties solid, melting point 206-209 ℃. Pergolide mesylate (Pergolide Mesylate):C19H26N2S?CH4O3S. [66104-23-2]. Crystallization, melting point 225 ℃ (decomposition); Melting point 258~260 ℃. UV maximum absorption (water):279nm(ε6385);(methanol):280nm(ε6980);(anhydrous ethanol):281nm(ε6993). [α]D20-18.0 ~-23.0 (C = 10 mg/ml, dimethylformamide). pKa(66% dimethylformamide) 7.8. Insoluble in dimethylformamide or methanol, slightly soluble in water, 0.01mol/L hydrochloric acid, chloroform, acetonitrile, dichloromethane or anhydrous ethanol, very slightly soluble in acetone, almost insoluble in 0.1mol/L sodium hydroxide, 0.1mol/L hydrochloric acid or ether. |
Use | The use of synthetic ergoline drugs, new dopaminergic agonists, its role is stronger, and long-acting. As an adjunctive therapeutic drug of levodopa and carbidopa, it is used for the treatment of Parkinson's disease. Antiparkinsonian drugs for the adjunctive treatment of Parkinson's disease |
UN IDs | UN 1544 6.1/PG II |
RTECS | KE6344964 |
Hazard Class | 6.1 |
Packing Group | II |
Merck | 14,7162 |